138 related articles for article (PubMed ID: 10749323)
1. Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: discrepant findings in tissue versus stool.
Limburg PJ; Ahlquist DA; Gilbert JA; Harrington JJ; Klee GG; Roche PC
Dig Dis Sci; 2000 Mar; 45(3):494-9. PubMed ID: 10749323
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms.
Baldus SE; Hanisch FG; Kotlarek GM; Zirbes TK; Thiele J; Isenberg J; Karsten UR; Devine PL; Dienes HP
Cancer; 1998 Mar; 82(6):1019-27. PubMed ID: 9506345
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity of Lewis blood group and mucin peptide core antigens: correlations with grade of dysplasia and malignant transformation in the colorectal adenoma-carcinoma sequence.
Baldus SE; Hanisch FG; Pütz C; Flucke U; Mönig SP; Schneider PM; Thiele J; Hölscher AH; Dienes HP
Histol Histopathol; 2002 Jan; 17(1):191-8. PubMed ID: 11813869
[TBL] [Abstract][Full Text] [Related]
4. Significance of MUC1 and MUC2 mucin expression in colorectal cancer.
Ajioka Y; Allison LJ; Jass JR
J Clin Pathol; 1996 Jul; 49(7):560-4. PubMed ID: 8813954
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma.
Baldus SE; Mönig SP; Hanisch FG; Zirbes TK; Flucke U; Oelert S; Zilkens G; Madejczik B; Thiele J; Schneider PM; Hölscher AH; Dienes HP
Histopathology; 2002 May; 40(5):440-9. PubMed ID: 12010364
[TBL] [Abstract][Full Text] [Related]
6. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma.
Nakamori S; Ota DM; Cleary KR; Shirotani K; Irimura T
Gastroenterology; 1994 Feb; 106(2):353-61. PubMed ID: 7905449
[TBL] [Abstract][Full Text] [Related]
7. Products of Chemoenzymatic Synthesis Representing MUC1 Tandem Repeat Unit with T-, ST- or STn-antigen Revealed Distinct Specificities of Anti-MUC1 Antibodies.
Yoshimura Y; Denda-Nagai K; Takahashi Y; Nagashima I; Shimizu H; Kishimoto T; Noji M; Shichino S; Chiba Y; Irimura T
Sci Rep; 2019 Nov; 9(1):16641. PubMed ID: 31719620
[TBL] [Abstract][Full Text] [Related]
8. Basic studies on a labeled anti-mucin antibody detectable by infrared-fluorescence endoscopy.
Bando T; Muguruma N; Ito S; Musashi Y; Inayama K; Kusaka Y; Tadatsu M; Kunio I; Irimura T; Shibamura S; Takesako K
J Gastroenterol; 2002; 37(4):260-9. PubMed ID: 11993509
[TBL] [Abstract][Full Text] [Related]
9. Correlation of the immunohistochemical reactivity of mucin peptide cores MUC1 and MUC2 with the histopathological subtype and prognosis of gastric carcinomas.
Baldus SE; Zirbes TK; Engel S; Hanisch FG; Mönig SP; Lorenzen J; Glossmann J; Fromm S; Thiele J; Pichlmaier H; Dienes HP
Int J Cancer; 1998 Apr; 79(2):133-8. PubMed ID: 9583726
[TBL] [Abstract][Full Text] [Related]
10. Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues.
Balmaña M; Duran A; Gomes C; Llop E; López-Martos R; Ortiz MR; Barrabés S; Reis CA; Peracaula R
Int J Biol Macromol; 2018 Jun; 112():33-45. PubMed ID: 29408556
[TBL] [Abstract][Full Text] [Related]
11. Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterogeneous tumor-associated aberrations in glycosylation.
Cao Y; Blohm D; Ghadimi BM; Stosiek P; Xing PX; Karsten U
J Histochem Cytochem; 1997 Nov; 45(11):1547-57. PubMed ID: 9358856
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the major sialyl-Lex-positive mucins present in colon, colon carcinoma, and sera of patients with colorectal cancer.
Hanski C; Hanski ML; Zimmer T; Ogorek D; Devine P; Riecken EO
Cancer Res; 1995 Feb; 55(4):928-33. PubMed ID: 7850810
[TBL] [Abstract][Full Text] [Related]
13. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression.
Reis CA; David L; Correa P; Carneiro F; de Bolós C; Garcia E; Mandel U; Clausen H; Sobrinho-Simões M
Cancer Res; 1999 Mar; 59(5):1003-7. PubMed ID: 10070955
[TBL] [Abstract][Full Text] [Related]
14. [Expression and clinical significance of Mucin and E-cadherin in colorectal tumors].
Yu XW; Rong W; Xu FL; Xu GY; Sun YR; Feng MY
Ai Zheng; 2007 Nov; 26(11):1204-10. PubMed ID: 17991319
[TBL] [Abstract][Full Text] [Related]
15. Detection and isolation of MUC1 mucin from larynx squamous cell carcinoma.
Croce MV; Price MR; Segal-Eiras A
Pathol Oncol Res; 2000; 6(2):93-9. PubMed ID: 10936782
[TBL] [Abstract][Full Text] [Related]
16. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
17. A novel monoclonal antibody, H9, directed against the core protein of MUC1 mucin.
Hamada H; Kohno N; Yokoyama A; Kondo K; Yang SZ; Hiwada K; Watanabe K; Miyake M
Oncol Rep; 2000; 7(2):225-32. PubMed ID: 10671662
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer.
Baldus SE; Zirbes TK; Glossmann J; Fromm S; Hanisch FG; Mönig SP; Schröder W; Schneider PM; Flucke U; Karsten U; Thiele J; Hölscher AH; Dienes HP
Oncology; 2001; 61(2):147-55. PubMed ID: 11528254
[TBL] [Abstract][Full Text] [Related]
19. Expression of CA19-9, DU-PAN-2, and SPan-1 antigens on two types of normal salivary mucins.
Ho JJ; Norton K; Chung YS; Kim YS
Oncol Res; 1993; 5(9):347-56. PubMed ID: 7518709
[TBL] [Abstract][Full Text] [Related]
20. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer.
Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K
J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
